NCT05144776Completed
Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool
Evaluation of Novel Hepatitis B DNA Test from Capillary Blood At the Point-of-care As a Tool to Enhance Clinical Management
Source: ClinicalTrials.gov · Last updated 6 Mar 2025
Brief summary (registry, in English)
This is a cross sectional observational study to asses the performance of two novel HBV DNA testing methodologies; a) dried blood spot sampling and b) fingerstick capillary blood using the Xpert® Hepatitis B Virus viral load assay. Both novel testing methodologies will be compared with venous blood tested using a gold standard HBV DNA assay. The sensitivity and specificity of the two novel testing will be evaluated. HBV viral load tests are essential to guide antiviral treatment eligibility and effectiveness. However, many people are unable to access these tests, particularly those living in remote or limited resources settings given high cost, or unavailable infrastructure. Simple, affordable and accessible HBV viral load tests are required to increase global access to HBV testing and treatment to meet the WHO HBV elimination targets. The GeneXpert Diagnostic Systems, the most common molecular point-of-care platform globally, has the potential to provide simple and affordable HBV viral load tests. Dried Blood Spot testing is also an affordable and accessible testing methodology particularly suited to remote and resource limited settings. This proof-of-concept study will assess the feasibility and diagnostic performance of Xpert® HBV Viral Load test and Dried Blood Spot testing for the quantitation of HBV DNA from fingerstick capillary samples.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 268 (actual)
- First submitted
- 22 Nov 2021
- Start date
- 17 Nov 2022
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Kirby Institute
- Diseases
- Hepatitis B
- NCT number
- NCT05144776
What you commit to
- Study type: Observational
- Participants enrolled: 268
- From 17 Nov 2022 to the primary completion date, 1 Jun 2024
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Nil
Who the study is looking for
- Have voluntarily signed the informed consent form, 18 years of age or older, HBsAg positive
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St Vincent's Hospital Melbourne Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| STORR Liver Centre Westmead Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
| Blacktown Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
| St Vincent's Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
| Liverpool Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.